These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 2730266

  • 1. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
    Barakat S, Melmed S.
    Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Somatostatin analogs in the treatment of acromegaly.
    Lamberts SW, Reubi JC, Krenning EP.
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R.
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
    Kurahashi K, Endo I, Kondo T, Morimoto K, Yoshida S, Kuroda A, Aihara KI, Matsuhisa M, Nakajima K, Mizobuchi Y, Nagahiro S, Abe M, Fukumoto S.
    Intern Med; 2017 Sep 15; 56(18):2455-2461. PubMed ID: 28824054
    [Abstract] [Full Text] [Related]

  • 13. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
    Gradiser M, Matovinovic M, Vrkljan M.
    Croat Med J; 2007 Feb 15; 48(1):87-91. PubMed ID: 17309144
    [Abstract] [Full Text] [Related]

  • 14. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug 15; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 15. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
    Yoenem A, Cakyr B, Azal O, Corakcy A, Kutlu M, Oezata M.
    Endocr Regul; 1999 Dec 15; 33(4):169-74. PubMed ID: 10700085
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Presurgical octreotide treatment in acromegaly.
    Stevenaert A, Beckers A.
    Acta Endocrinol (Copenh); 1993 Jul 15; 129 Suppl 1():18-20. PubMed ID: 8372606
    [Abstract] [Full Text] [Related]

  • 18. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
    Harinarayan CV.
    J Indian Med Assoc; 2004 May 15; 102(5):258, 260-1. PubMed ID: 15636029
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.